Oncotelic Therapeutics Current Ratio 1970-1969 | OTLC
Oncotelic Therapeutics current ratio from 1970 to 1969. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
|Oncotelic Therapeutics Current Ratio Historical Data
||Medical - Biomedical and Genetics
Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting the TGF-beta2 mRNA. Mateon is conducting a Phase 2/3 clinical trial of OT-101 in patients suffering from COVID-19. In addition, the company has initiated a global Phase 4 clinical trial of ArtiShield(TM) in India, Africa, and Latin America for the treatment of COVID-19, with results expected in the 4Q20. ArtiShieldTM received marketing approval from India.